Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Division of Immunobiology, Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Front Immunol. 2019 Dec 12;10:2893. doi: 10.3389/fimmu.2019.02893. eCollection 2019.
Obesity is a prevalent predisposing factor to non-alcoholic fatty liver disease (NAFLD), the most common chronic liver disease in the developed world. NAFLD spectrum of disease involves progression from steatosis (NAFL), to steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma (HCC). Despite clinical and public health significance, current FDA approved therapies for NAFLD are lacking in part due to insufficient understanding of pathogenic mechanisms driving disease progression. The etiology of NAFLD is multifactorial. The induction of both systemic and tissue inflammation consequential of skewed immune cell metabolic state, polarization, tissue recruitment, and activation are central to NAFLD progression. Here, we review the current understanding of the above stated cellular and molecular processes that govern macrophage contribution to NAFLD pathogenesis and how adipose tissue and liver crosstalk modulates macrophage function. Notably, the manipulation of such events may lead to the development of new therapies for NAFLD.
肥胖是导致非酒精性脂肪性肝病(NAFLD)的一个普遍危险因素,NAFLD 是发达国家最常见的慢性肝病。NAFLD 疾病谱涉及从脂肪变性(NAFL)进展为脂肪性肝炎(NASH)、肝硬化和肝细胞癌(HCC)。尽管具有临床和公共卫生意义,但目前美国食品药品监督管理局(FDA)批准的 NAFLD 治疗方法缺乏部分原因是对导致疾病进展的发病机制的理解不足。NAFLD 的病因是多因素的。由于免疫细胞代谢状态、极化、组织募集和激活的偏斜,导致全身性和组织炎症的诱导,是 NAFLD 进展的核心。在这里,我们回顾了目前对上述控制巨噬细胞参与 NAFLD 发病机制的细胞和分子过程的理解,以及脂肪组织和肝脏相互作用如何调节巨噬细胞功能。值得注意的是,对这些事件的操纵可能会导致开发新的 NAFLD 治疗方法。